References
- Nugent RA, Fathima SF, Feigl AB, et al. The burden of chronic kidney disease on developing nations: a 21st century challenge in global health. Nephron Clin Pract 2011;118:c269-77
- Roderick P, Nicholson T, Armitage A, et al. An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales. Health Technol Assess 2005;9:1-178
- Schiller B, Doss S, De Cock E, et al. Cost of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study. Hemodial Int 2008;12:441-9
- Kerr PG. Renal anaemia: recent developments, innovative approaches and future directions for improved management. Nephrology 2006;11:542-8
- Saueressig U, Kwan JTC, De Cock E, et al. Healthcare resource utilization for anemia management: current practice with erythropoiesis-stimulating agents and the impact of converting to once-monthly C.E.R.A. Blood Purif 2008;26:537-46
- Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002;13:504-10
- Perlman RL, Finkelstein FO, Liu L, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis 2005;45:658-66
- Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004;19:121-32
- Silverberg D, Wexler D, Blum M, et al. The cardio-renal anaemia syndrome: does it exist? Nephrol Dial Transplant 2003;18(Suppl 8):vii7-12
- Foley RN, Parfrey PS, Harnett JD, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61
- Gouva C, Nikolopoulos P, Ioannidis JPA, et al. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004;66:753-60
- Locatelli F, Aljama P, Bárány P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(Suppl 2):ii1-47
- Churchill DN, Macarios D, Attard C, et al. Costs associated with erythropoiesis-stimulating agent administration to hemodialysis patients. Nephron Clin Pract 2007;106:c193-8
- Levin NW, Fishbane S, Valdés Cañedo F, et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007;370:1415-21
- Locatelli F, Mann JFE, Aldigier J-C, et al. C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease. Clin Nephrol 2010;73:94-103
- Sulowicz W, Locatelli F, Ryckelynck JP, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007;2:637-46
- Carrera F, Lok CE, de Francisco A, et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant 2010;25:4009-17
- Mann JF, de Francisco A, Nassar G, et al. Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease. Clin Nephrol 2011;76:9-15
- Klatko W, Felisiak J. Time and motion study of anaemia management with erythropoiesis stimulating agents in haemodialysis units in Poland. JHPOR 2012;1:116-21
- Burnier M, Douchamps JA, Tanghe A, et al. Less frequent dosing of erythropoiesis stimulating agents in patients undergoing dialysis: a European multicentre cost study. J Med Econ 2009;12:77-86